Downregulation of protein tyrosine kinases is a major function of the multidomain protein c-Cbl. This effect of c-Cbl is critical for both negative regulation of normal physiological stimuli and suppression of cellular transformation. In spite of the apparent importance of these effects of c-Cbl, their own regulation is poorly understood. To search for possible novel regulators of c-Cbl, we purified a number of c-Cbl-associated proteins by affinity chromatography and identified them by mass spectrometry. Among them, we identified the UBA-and SH3-containing protein T-cell Ubiquitin LigAnd (TULA), which can also bind to ubiquitin. Functional studies in a model system based on co-expression of TULA, c-Cbl, and EGF receptor in 293T cells demonstrate that TULA is capable of inhibiting c-Cbl-mediated downregulation of EGF receptor. Furthermore, modulation of TULA concentration in Jurkat T-lymphoblastoid cells demonstrates that TULA upregulates the activity of both Zap kinase and NF-AT transcription factor. Therefore, our study indicates that TULA counters the inhibitory effect of cCbl on protein tyrosine kinases and, thus, may be involved in the regulation of biological effects of c-Cbl. Finally, our results suggest that TULA-mediated inhibition of the effects of c-Cbl on protein tyrosine kinases is caused by TULA-induced ubiquitylation and degradation of c-Cbl.
Introduction
c-Cbl is a ubiquitously expressed cytoplasmic protein, which consists of a tyrosine kinase-binding (TKB) 1 region, a RING finger, a proline-rich region, and a Cterminal region featuring both a leucine zipper (LZ) and a ubiquitylation-associated domain (UBA). Genetic and biochemical studies indicate that attenuation of signaling mediated by protein tyrosine kinases (PTKs) is a major function of c-Cbl (reviewed in Sanjay et al., 2001; Tsygankov et al., 2001; Rao et al., 2002a) . In most cases, this function of c-Cbl is mediated by its E3 ubiquitin-protein ligase activity, which depends on the RING finger linking c-Cbl to an E2 ubiquitin-conjugating enzyme (Joazeiro et al., 1999; Levkowitz et al., 1999; Waterman et al., 1999; Yokouchi et al., 1999; Zheng et al., 2000) and the TKB region linking c-Cbl to an activated PTK (Meng et al., 1999; Miyake et al., 1999) . Binding of c-Cbl, E2, and activated PTK induces ubiquitylation of the PTK followed by its degradation and, hence, a decrease in its overall kinase activity (Lee et al., 1999; Levkowitz et al., 1999; Miyake et al., 1999; Wang et al., 1999; Waterman et al., 1999; Yokouchi et al., 1999 Yokouchi et al., , 2001 Andoniou et al., 2000; Lill et al., 2000; Ota et al., 2000; Rao et al., 2001 Rao et al., , 2002b Mosesson et al., 2003) .
The ability of c-Cbl to inhibit PTKs underlies its biological functions, which include attenuation of positive selection of thymocytes (Naramura et al., 1998) and, generally, of proliferation of lymphoid and nonlymphoid cells (Murphy et al., 1998; Lee et al., 1999) . Also, c-Cbl-mediated downregulation of EGFR and PDGFR reduces proliferation of fibroblasts in culture (Broome et al., 1999; Miyake et al., 1999) . Furthermore, ectopic expression of c-Cbl suppresses in vivo growth of neuroblastoma transformed with Neu, a rodent homologue of the human HER-2/ErbB-2 PTK, which belongs to the EGFR family and is known to promote metastatic breast cancer (Levkowitz et al., 2000) . Downregulation of HER-2 by EGF or anti-HER-2 requires ubiquitylation of HER-2 and its binding to cCbl, thus arguing that the therapeutic potential of anti-HER-2 antibodies is dependent on the interactions between c-Cbl and HER-2 . The involvement of c-Cbl in tumor suppression is further proven by the findings that the transformation potential of the oncogenic forms of Met and Fms, PTK receptors of HGF and CSF-1, respectively, is linked to their inability to get associated with c-Cbl, which binds to and targets to degradation wild-type Met and Fms (Mancini et al., 2002; Peschard et al., 2001; Wilhelmsen et al., 2002) . Finally, Cbl-b, a mammalian Cbl-family protein, has also been shown to downregulate EGFR (Ettenberg et al., , 2001 . However, in spite of the apparent importance of the regulatory effects of c-Cbl on PTKs, their own regulation is poorly understood and requires further elucidation.
In this report, we identify a novel c-Cbl-binding protein. This protein is a product of the UBASH3A gene, which has been examined for its potential role in autosomal recessive nonsyndromic deafness and ruled out as a possible reason for this condition (Wattenhofer et al., 2001) . Our results indicate that this protein is primarily expressed in T lymphocytes and other lymphoid cells and is capable of binding to ubiquitin. Thus, we named it T-cell Ubiquitin LigAnd (TULA). Functional studies indicate that TULA inhibits c-Cblmediated downregulation of EGFR in 293T cells. Furthermore, Jurkat T cells transfected to overexpress TULA show an increase in NF-AT transcription activity, whereas those transduced to express TULAspecific siRNA exhibit the reduced activity of both NF-AT and Zap, a c-Cbl-targeted T-cell-specific PTK. Our study further suggests that the effects of TULA may be caused by its ability to induce degradation of c-Cbl. Overall, the obtained results are consistent with the notion that TULA acts as a negative regulator of cCbl-mediated inhibition of PTKs and, thus, may promote cellular transformation.
Results

Identification of TULA as a c-Cbl-associated protein
To co-purify c-Cbl-associated proteins, we used a two-step affinity chromatography procedure. First, lysate of JMC-D3 cells was subjected to Ni 2 þ -chelation chromatography. The presence of a stretch of seven histidines in the N-terminal region of c-Cbl allowed us to obtain a c-Cbl-enriched fraction, which was subjected to anti-c-Cbl immunoaffinity chromatography. Proteins bound to anti-c-Cbl were eluted with pH3 glycine buffer, separated using SDS-PAGE (Figure 1a) , and identified using mass spectrometry (Figure 1c, d) .
This method of identification of novel c-Cbl-associated proteins was validated in two ways. First, immunoblotting of the fractions revealed co-purification of c-Cbl with its known binding partners, CrkL and PI-3 0 kinase p85, but not with Rac1 or Akt ( Figure 1b and data not shown). Furthermore, CrkL and PI-3 0 kinase p85, as well as CIN85, another protein previously shown to be associated with c-Cbl (reviewed in Tsygankov et al., 2001) , were identified by us among proteins copurified with c-Cbl (Figure 1d ), thus providing an internal positive control.
One of the identified c-Cbl-associated proteins turned out to be a product of the UBASH3A gene (Wattenhofer et al., 2001) . This protein contained an N-terminal UBA domain followed by an SH3 domain and a homology region of unknown function, termed an HCD domain (Figure 1d ). Considering that this protein was dissimilar to any of the known binding partners of c-Cbl, we decided to characterize it further.
Expression of TULA
The cDNA of TULA was obtained by RT-PCR using total RNA from JMC-D3 cells. Sequencing of the obtained clones identified two isoforms of TULA cDNA encoding for 661-and 623-amino-acid proteins (Figure 1f ), virtually identical to the alternatively spliced forms found in placenta (Wattenhofer et al., 2001) . The number of bacterial colonies harboring plasmids with the short form of TULA, which lacks exon 5, was fivefold higher than that with the long form (data not shown).
Using Northern blotting, we detected TULA mRNA in thymus and spleen, as well as in Jurkat, JMC-D3, and Ramos cell lines (Figure 2a) . The major species of TULA mRNA has a length of 2.5 kb, consistent with the length of the TULA coding sequence. Further analysis using RT-PCR yielded similar results; a strong band corresponding to TULA mRNA was seen in thymus, spleen, bone marrow, and lung, as well as in T and B cells, whereas in other tissues or in myeloid and epithelial cells the band indicative of TULA mRNA was either absent or extremely faint (Figure 2b ). Considering that TULA mRNA was detected in the lung, but not in 293T or COS epithelial cell lines, we further analysed its expression in a panel of epithelial cell lines, which included one cell line of lung origin. The failure of these experiments to detect TULA mRNA in the cell lines analysed (Figure 2c ) suggested that TULA is expressed in epithelial cells at a very low level, if at all. The specificity of DNA amplification was assured by using nested PCR and verified using Southern blotting of the amplified fragments (data not shown). To assess the expression of alternatively spliced forms of TULA, we carried out RT-PCR with primers that amplify easily discernible products of different length using these forms as templates. The amount of the short form of TULA was significantly higher than that of the long form in all the TULA-positive samples examined (Figure 2b ).
Anti-TULA immunoblotting of lysates of various human cell lines detected TULA in T and B cells, but not in myeloid or epithelial cells (Figure 2d and data not shown). Consistent with PCR results, endogenous TULA co-migrated with its short form expressed ectopically in 293T cells (Figure 2d ). Taken together with TULA mRNA expression results, these experiments indicated that TULA is expressed primarily in lymphoid cells and primarily in its short form. (a) A silver-stained SDS-PAGE gel presents the major fractions obtained in the course of affinity purification of c-Cbl-associated proteins. The final fractions from the anti-c-Cbl column were concentrated using StrataClean resin (Stratagene), and the adjusted sample volumes corresponding to 300 ml of fractions prior to concentration were analysed. (b) Immunoblotting of the major fractions obtained by affinity purification of c-Cbl-associated proteins. The proteins detected are indicated by arrowheads. (c) Protein bands co-purified with c-Cbl were stained with colloidal Coomassie and excised from the gel. Proteins identified by mass spectrometry in the eluate, but not in the last wash, and the peptides used for their identification are shown in (d) EF-1a is an exception to this pattern, being present in the last, but not in the first wash, which is not shown. A schematic view of TULA (e) and its cDNA from JMC-D3 cells (f) is shown. The short form of TULA lacks nucleotides between the two black arrowheads. This change results in the replacement of the italicized amino acids with a single residue of aspartic acid. Nucleotides that are different in the placental sequence are shown at the top of the T-cell sequence. The UBA, SH3, and HCD domains are underlined with dashed, solid double and solid single lines, respectively. A putative nuclear localization site is shaded.
[DUBA]TULA lacks the sequence between open arrowheads. The SH3-defective TULA has a tg-ct substitution in the positions marked with asterisks corresponding to a W279L mutation (numbering is for the short form)
Subcellular distribution of TULA
The presence of a potential nuclear localization site in TULA (see Figure 1f ) argued in favor of its nuclear localization, whereas c-Cbl is cytoplasmic (reviewed in Tsygankov et al., 2001) . This apparent contradiction compelled us to evaluate the subcellular distribution of TULA. Since the available antipeptide antibodies to TULA did not allow us to reliably quantify endogenous TULA, we performed this analysis using TULA-transfected 293T cells. The experiments showed that TULA was present in all the fractions examined, with at least 70% of it located outside the nucleus (Figure 3 ). The level of TULA expression did not affect its subcellular distribution to an appreciable extent (Figure 3b ), assuring us that the observed result was not an overexpression artifact. Treatment of cells with pervanadate had no substantial effect on the distribution of TULA (Figure 3a) , indicating that it was independent of tyrosine phosphorylation. Finally, the experiments showed a difference between the splice forms of TULA; although both were largely extra-nuclear, the fraction of short TULA in the nucleus was higher than that of the long form (Figure 3a,c) .
Association of TULA with c-Cbl
The finding that TULA remains specifically associated with c-Cbl following a lengthy purification procedure that includes two chromatography steps indicates that their binding is very strong. To further examine the association of c-Cbl with TULA, we employed three independent approaches. First, GST-fusion proteins encompassing a long or a short form of TULA were used for in vitro binding ('pull-down') assays with cell lysates containing c-Cbl. In these experiments, we initially used lysates of 293T cells transfected with control or c-Cbl-expression vectors. GST-TULA, but not free GST, pulled down c-Cbl from c-Cbl-positive 293T cell lysates (Figure 4a) . Notably, short TULA trapped 3-10% of total c-Cbl under these conditions, whereas the long form was significantly less efficient (data not shown). Likewise, GST-TULA pulled down cCbl from lysates of Jurkat and Ramos, lymphoid cell lines expressing an appreciable level of endogenous cCbl (data not shown). Second, TULA was co-expressed with c-Cbl in 293T cells, and their association was examined using c-Cbl immunoprecipitation followed by anti-V5 immunoblotting of V5-tagged TULA. The short form of TULA was shown to strongly co-immunoprecipitate with c-Cbl, whereas the presence of long TULA in c-Cbl immunoprecipitates was revealed only after a very long exposure (Figure 4b and data not shown). Third, endogenous TULA and c-Cbl were co-immunoprecipitated from Jurkat and Ramos cell lysates using anti-c-Cbl (Figure 4c ). Endogenous TULA from these immune complexes co-migrated with the short form of TULA forced-expressed in 293T cells (Figure 4c ). RT-PCR (b, c) . In (b) and (c), the identity of TULA bands indicated by arrowheads was confirmed using Southern blotting with a TULA-specific cDNA probe (not shown). PCR amplification of equal amounts of short and long TULA cDNA was used to confirm that both forms were amplified with equal efficiency and as the size controls in (c). b-actin RNA was used to indicate the total amount of RNA in (a-c). Considering that the expression of short TULA in cell lines and tissues was higher than that of its long form (Figure 2b) , and that the binding of short TULA to cCbl exceeded that of the long form dramatically (Figure 4b ), we conducted all our subsequent experiments with the short form.
The experiments described in the previous paragraph indicated that the association of TULA and c-Cbl does not require cell stimulation in any of the systems utilized to evaluate it (Figure 4) , thus arguing that this association is constitutive. Since TULA has an SH3 domain and c-Cbl has a number of proline-rich motifs (Figure 5a) , we examined the role of SH3-mediated interactions in the association of TULA and c-Cbl.
[W279L]TULA, an SH3-defective mutant form of TULA, was incapable of binding to wild-type c-Cbl as demonstrated by the lack of their co-immunoprecipitation (Figure 5b ). Consistent with this result, the loss of the proline-rich region of c-Cbl between amino-acid residues 480 and 655 abrogated binding of c-Cbl to TULA, whereas the loss of c-Cbl major tyrosine phosphorylation sites or even the entire C-terminal region (656-906) had no effect (Figure 5c ).
The C-terminal region of c-Cbl containing UBA and LZ motifs mediates its dimerization , consistent with the well-known role of LZ (Pabo and Sauer, 1992) and the recently described role of UBA (Bertolaet et al., 2001a) . Therefore, the contribution of the UBA domain of TULA to c-Cbl/TULA interactions was assessed using co-immunoprecipitation of c-Cbl with either wild-type TULA or [DUBA]TULA, a deletion mutant of TULA lacking the UBA domain. Although co-immunoprecipitation of [DUBA]TULA with c-Cbl was somewhat weaker than that of wild-type TULA, the UBA of TULA was not essential to c-Cbl/ TULA binding (Figure 5d ). This finding is in agreement with the results indicating that the loss of c-Cbl's UBA (in HUT-Cbl) does not interfere with c-Cbl/TULA association ( Figure 5c ). To confirm the results obtained in co-immunoprecipitation experiments, we carried out pull-down assays using the GST-fused UBA domain of c-Cbl and lysates of 293T cells overexpressing wild-type TULA. No binding of TULA to c-Cbl's UBA was detected (data not shown), in agreement with the notion that UBA does not play an important role in c-Cbl/ TULA interactions.
Association of TULA and c-Cbl with ubiquitin
Since UBA domains of several proteins can bind to ubiquitin (Bertolaet et al., 2001b; Wilkinson et al., 2001) , we evaluated interactions of TULA and c-Cbl with agarose-immobilized ubiquitin and the role of UBA in these interactions. This analysis indicated that both TULA and c-Cbl were capable of binding to ubiquitin, and that in both cases the presence of UBA was essential (Figure 5e ). It should be noted that the ability to bind to ubiquitin differed considerably for TULA and c-Cbl; B50% of TULA, but only 0.3% of cCbl was found associated with ubiquitin beads in our experimental system (data not shown). The reason for this disparity is unclear; it may have been caused by intrinsic differences between the UBA domains of TULA and c-Cbl, as well as by blocking of the UBA domain of c-Cbl as a result of c-Cbl dimerization . Regardless, these results indicate that TULA strongly binds to ubiquitin.
Effects of TULA on ubiquitylation and degradation of EGFR
Considering that TULA binds to both ubiquitin and cCbl, we decided to assess the effects of TULA on c-Cblmediated downregulation of PTKs, which is dependent on the c-Cbl-mediated ubiquitylation of these kinases. We selected EGFR for the initial characterization of these effects, since its c-Cbl-dependent ubiquitylation and degradation has been studied in great detail (Levkowitz et al., 1998 Waterman et al., 1999 Waterman et al., , 2002 Yokouchi et al., 1999; Lill et al., 2000;  Alwan et al., 2003; Bao et al., 2003; Duan et al., 2003; Haglund et al., 2003; Jiang et al., 2003; Mosesson et al., 2003) . Furthermore, although the EGFR-based experimental system is unlikely to mimic functions of TULA in lymphocytes, in which TULA is expressed primarily, the interactions between EGFR, cCbl, and TULA may still be of physiological relevance, since it is possible that TULA is expressed in some epithelial cells, albeit at a level lower than that in lymphocytes. This notion is based on the finding that although TULA mRNA was not detected in nonlymphoid tissues by Northern blotting, the RT-PCR product corresponding to TULA mRNA was seen in lung and, possibly, kidney ( Figure 2b ). TULA, c-Cbl, and EGFR were co-expressed in 293T cells in various combinations, and the levels of all these proteins were 6 cells), and their whole-cell lysates (WCLs) were analysed using pull-down assays with GST or GST-TULA (short form), as indicated at the top of the panel. Pulled-down proteins and WCLs were separated using SDS-PAGE and immunoblotted with anti-c-Cbl. The results from the same gel are presented, but a shorter exposure is shown for the WCL portion. (b) 293T cells were transfected with c-Cbl (100 ng per 1 Â 10 6 cells) and/or TULA (500 ng per 1 Â 10 6 cells) expression constructs or matching empty pAlterMAX, as indicated at the top of the panel and lysed. WCLs (100 mg of total protein per lane) and anti-Cbl immunoprecipitates (2 mg of total protein per sample) were separated using SDS-PAGE and immunoblotted with the antibodies indicated. Cells were stimulated with pervanadate (PV), where shown. (c) Endogenous c-Cbl was immunoprecipitated from the lysates of unstimulated cell lines indicated at the top of the panel with anti-c-Cbl or normal rabbit IgG (NRIgG). The amount of total protein used for immunoprecipitation was 3 mg for Jurkat and Ramos cell lines and 400 mg for 293T cells. The latter were transfected to express c-Cbl and/or TULA as described in (b). Immune complexes were obtained using protein G-agarose, separated using SDS-PAGE and probed with the antibodies indicated. The detected proteins are indicated by arrowheads. The positions of protein markers and their molecular masses in kDa are shown at the right of each panel determined. As expected, the level of EGFR dropped in response to EGF, and c-Cbl facilitated this process ( Figure 6a ). The presence of TULA inhibited EGFinduced degradation of EGFR upon 10-min stimulation with EGF; a c-Cbl-dependent decrease in EGFR level was 10-fold in the absence of ectopic TULA, but less than threefold in its presence (Figure 6a ). Although the effect of TULA on EGF-induced degradation of EGFR was more profound in the cells transfected to overexpress c-Cbl, it was also detectable in the cells transfected with an empty vector, which lacked ectopic c-Cbl and expressed endogenous c-Cbl only.
The effect of TULA on c-Cbl-dependent ubiquitylation of EGFR was also apparent. Immunoblotting of tyrosine-phosphorylated EGFR from cells co-expressing EGFR with c-Cbl, using antibodies to both total phosphotyrosine and a specific tyrosine phosphorylation site of EGFR (Tyr-1173), showed a profound up-smear (Figure 6a ), which is indicative of PTK ubiquitylation (Miyake et al., 1998; Waterman et al., 1999; Rao et al., 2001; Longva et al., 2002) . However, when EGFR and c-Cbl were co-expressed with TULA, the amount of upshifted bands greatly decreased ( Figure 6a ). This negative effect of TULA on EGFR ubiquitylation was 293T cells were transfected with expression constructs (100 ng for Cbl and 500 ng for short TULA per 1 Â 10 6 cells) or empty pAlterMAX, as indicated at the top of each panel. WCLs were separated using SDS-PAGE or first subjected to immunoprecipitation in (b-d) or precipitation with agarose-immobilized ubiquitin in (e) and then separated using SDS-PAGE. The separated proteins were analysed using immunoblotting with the antibodies indicated at the left of each panel. The amount of total protein loaded as WCL was 100 mg per lane. The amount of total protein used for immunoprecipitation was 2 mg per sample. The detected proteins are indicated by arrowheads. Cells were treated with pervanadate (PV) in (c) and (d), where indicated. The positions of protein markers and their molecular masses in kDa are shown at the right of each panel entirely consistent with its stabilizing effect on the total level of EGFR, since ubiquitylation of EGFR is thought to be a crucial step of its stimulation-induced degradation Miyake et al., 1999; Waterman et al., 1999; Lill et al., 2000; Duan et al., 2003) . To further analyse the effect of TULA on the stability of EGFR, we carried out additional experiments involving stimulation times up to 30 min, which confirmed the ability of TULA to inhibit both degradation and ubiquitylation of EGFR facilitated by c-Cbl (data not shown).
To ascertain that the stabilizing effect of TULA involves the mature EGFR located on the cell surface, we carried out EGFR downregulation assays, which indicated that TULA inhibits EGF-induced downregulation of surface EGFR facilitated by c-Cbl (Figure 6b ). In order to evaluate the biological outcome of an increase in the stability of EGFR induced by TULA, we used the SRE luciferase reporter construct. These experiments showed that TULA effectively abrogates the negative effect of c-Cbl on EGFR-mediated signaling (Figure 6c ). It should be noted that in experiments examining both the stability of EGFR (Figure 6a ) and the EGFR-dependent SRE transcription (Figure 6c) we observed a considerable effect of TULA even in the absence of stimulation. However, this effect is unlikely to be truly stimulation-independent and is probably caused by the constitutive low-level activation of EGFR due to its inevitable overexpression in 293T cells.
Effects of TULA on T-cell antigen receptor signaling
Considering that TULA is primarily expressed in lymphoid cells, we next examined the effects of TULA on PTK-dependent signaling in T cells. Based on the results of the experiments in 293T cells, one could speculate that TULA inhibits the downregulatory effects of c-Cbl on lymphoid PTKs involved in receptor signaling and, thus, upregulates this signaling. Jurkat T-lymphoblastoid cells were transiently co-transfected with a TULA expression construct and an NF-AT reporter, and the transcriptional activity of NF-AT was assayed in response to anti-CD3, which crosslinks the T-cell receptor (TCR)/CD3 complex and triggers TCR/CD3-mediated signaling. Specifically, NF-AT activity is a good measure of the TCR/CD3 signaling mediated by the T-cell-specific PTK Zap (Williams et al., 1998) . These experiments demonstrated that ectopic expression of wild-type TULA increased the response of NF-AT to CD3 crosslinking, in agreement with the notion that an increase in the level of wild-type TULA should diminish the effect of endogenous c-Cbl and, hence, facilitate TCR/CD3 signaling in the transfected cells (Figure 7a ). To further examine the issue of whether or not the effect of TULA was due to its ability to suppress c-Cbl-mediated inhibition of signaling, we transfected Jurkat cells to express ectopic c-Cbl with or without ectopic TULA. Ectopic expression of cCbl alone, as expected, reduced the NF-AT response to anti-CD3, whereas co-expression of ectopic TULA effectively countered c-Cbl-mediated downregulation of signaling (Figure 7a ).
To evaluate the effect of endogenous TULA on the TCR/CD3-induced activation of NF-AT, we utilized Jurkat cells with the reduced levels of endogenous TULA, which were generated using the TULA siRNAencoding gene transfer vector. The level of TULA expression in these cells was significantly decreased as compared to that in parental Jurkat cells and in those transduced with the vector encoding for control siRNA (Figure 7b ). Jurkat cells with the reduced level of endogenous TULA showed a substantial decrease in the response of NF-AT to anti-CD3 stimulation (Figure 7c) , which was consistent with the positive effect of ectopic TULA (Figure 7a) .
The finding that TULA exerts a positive effect on the TCR/CD3-mediated activation of NF-AT strongly suggests that TULA upregulates the kinase activity of Zap. To determine whether or not TULA indeed upregulates Zap, we examined tyrosine phosphorylation of Zap using its immunoprecipitation followed by antiphosphotyrosine immunoblotting. These experiments demonstrated that the TCR/CD3-mediated activation of Zap in Jurkat cells transduced with the TULA siRNA-encoding sequence was significantly lower than that in the control cells (Figure 7d ), thus indicating that TULA upregulates Zap activity in T cells.
Since it has been shown that c-Cbl is involved in downregulation of TCR/CD3 from the cell surface (Murphy et al., 1998; Naramura et al., 1998; , one might think that the observed effect of TULA on TCR/CD3 signaling is mediated by its effect on the surface expression of TCR/CD3. To evaluate this possibility, we examined the surface expression of CD3 on Jurkat cells expressing TULA-specific or control siRNA using flow cytometry and observed no significant difference between these cells (Figure 7e ).
Molecular basis of the observed effects of TULA
Our next goal was to characterize the molecular mechanisms of the observed effects of TULA. We chose to use overexpression of TULA, EGFR, and c-Cbl in 293T cells in these experiments, since the mechanism of c-Cbl-mediated ubiquitylation and degradation of EGFR has been studied in detail and since transfection of T cells failed to achieve expression levels of these proteins comparable to those found in 293T cells.
A possible explanation for the stabilizing effects of TULA on PTKs was provided by the finding that TULA induced not only an increase in the stability of EGFR, but also the concurrent opposite effect on c-Cbl; the level of c-Cbl was found to be decreased upon its coexpression with TULA and EGFR in the absence of EGF and was reduced further upon EGF stimulation (Figure 6a ). We next decided to assess a possible link between the observed decrease in the level of c-Cbl and ubiquitylation of c-Cbl, since the latter has been shown previously in several experimental systems (Wang et al., 1996 Yokouchi et al., 2001; Bao et al., 2003) . Ubiquitylation of c-Cbl was analysed using antiubiquitin immunoprecipitation followed by anti-c-Cbl immunoblotting of lysates of 293T cells expressing EGFR, c-Cbl, and TULA in various combinations. These experiments showed the appearance of highmolecular-weight ubiquitylated species of c-Cbl, when cCbl was co-expressed with both EGFR and TULA (Figure 8a ). Further studies demonstrated that the highmolecular-weight forms of c-Cbl were induced by EGF stimulation (data not shown). The degree of c-Cbl ubiquitylation was clearly lower than that of EGFR, since the high-molecular-weight forms of c-Cbl could only be detected in immunoprecipitates from aliquots containing considerable amounts of total cellular protein, whereas such forms were detectable for EGFR even in whole-cell lysate (see Figure 6a) . However, the apparent correlation of the TULA-induced decrease in the level of c-Cbl and the TULA-induced ubiquitylation of c-Cbl argued that c-Cbl underwent ubiquitylationdependent degradation in the presence of EGFR and TULA. This view was supported by real-time PCR analysis, which found no significant effect of TULA on the steady-state level of either c-Cbl or EGFR mRNA in 293T cells co-expressing TULA with c-Cbl and/or EGFR (data not shown).
The observed TULA-induced ubiquitylation of c-Cbl could be caused by c-Cbl itself (autoubiquitylation) or by a c-Cbl-specific E3 recruited by TULA. To address this issue, we carried out co-expression experiments and demonstrated that, unlike wild-type c-Cbl, the RINGdefective mutant of c-Cbl ([C381A]Cbl) was not degraded in the presence of EGFR and TULA (Figure 8b ). This result suggested that the E2-binding activity of c-Cbl is essential for the TULA-dependent degradation of c-Cbl, which, thus, is likely to be mediated by c-Cbl autoubiquitylation.
Considering that TULA's UBA tightly binds to ubiquitin (see Figure 5e ) and that this binding may interfere with ubiquitylation in the c-Cbl/E2/PTK system, we evaluated the role of TULA's UBA in the observed effects of TULA. Our results showed that [DUBA]TULA, unlike its wild-type form, diminished neither the c-Cbl-induced upshift of EGFR protein band (Figure 8c ) nor the c-Cbl-induced degradation of EGFR (Figure 8d) . Likewise, only wild-type TULA, but not [DUBA]TULA, reduced the protein level of c-Cbl in the presence of EGFR (Figure 8c, d ). Taken together, these results indicate that TULA's UBA is essential for the observed effects of TULA on c-Cbl and PTKs.
To complete the characterization of the effect of TULA on c-Cbl, we evaluated the contribution of a PTK to the TULA-dependent downregulation of c-Cbl. Since our results were consistent with the notion that a PTK is required for the TULA-dependent downregulation of c-Cbl (compare Figures 4 and 5 showing no effect of TULA on c-Cbl to Figure 6 indicating a strong effect of TULA on c-Cbl in the presence of EGFR), we decided to directly analyse this requirement by coexpressing TULA and EGFR with wild-type and TKBdefective c-Cbl. These experiments showed that [G306E]Cbl, a form of c-Cbl incapable of TKBmediated interactions with PTKs, was not degraded in the presence of EGFR and TULA (Figure 8b ), thus arguing that these interactions are essential for the TULA-dependent downregulation of c-Cbl.
Discussion
Functional domains and expression of TULA
In this report, we identify TULA as a c-Cbl-associated protein and a possible modulator of the effect of c-Cbl on PTKs. TULA features three distinct domains. Functions of HCD, the C-terminal-most domain of TULA, are currently unknown. The UBA domain of TULA binds to ubiquitin (see Figure 5e ). The SH3 domain of TULA appears to play the major role in the binding of TULA to c-Cbl, since a mutation inactivating this domain or the loss of an SH3-binding region by cCbl abrogates the interactions between these proteins even at high expression levels (see Figure 5b,c) .
Although the involvement of UBA in the interactions between c-Cbl and TULA is possible in principle, since both TULA and c-Cbl possess this domain, which is capable of dimerization, the results of our experiments argue against a crucial role of UBA domains in the binding of TULA to c-Cbl. Firstly, the loss of UBA by either TULA or c-Cbl did not preclude binding between c-Cbl and TULA (see Figure 5c, d) . Secondly, no binding was observed between TULA and the GSTfused UBA domain of c-Cbl (data not shown). Likewise, the involvement of tyrosine phosphorylation in the interactions between TULA and c-Cbl can be ruled out, since (a) cell stimulation is not required for their association (see Figures 4, 5b-d) , (b) the loss of tyrosine phosphorylation sites by c-Cbl does not affect its binding to TULA (see Figure 5c) , and (c) no tyrosine phosphorylation of TULA has been detected in the cell systems utilized in our experiments, with or without stimulation (data not shown).
TULA, both at the protein and mRNA level, is expressed predominantly in lymphoid cells (see Figure 2) . These results are consistent with the data of the initial RT-PCR analysis of this gene at the mRNA level (Wattenhofer et al., 2001 ). In our experiments, the lung is a notable exception to the lymphoid expression pattern of TULA; furthermore, a weak signal corresponding to TULA mRNA is also seen in kidney (see Figure 2b) . However, the level of TULA mRNA in the lung and, especially, in kidney appears to be low, since it is detectable in these tissues using RT-PCR, but not the less sensitive Northern blotting. This finding and the lack of detectable TULA mRNA in cell lines of epithelial origin (see Figure 2b-d) suggest that the presence of TULA in the nonlymphoid tissues may be due to lymphoid infiltrates. Similarly, the presence of TULA mRNA in placenta reported earlier (Wattenhofer et al., 2001 ) is likely to be due to the contamination of placenta with blood. Indeed, we found no TULA mRNA in placenta, in spite of the higher across-theboard sensitivity of the TULA mRNA detection systems in our study as compared to that used by Wattenhofer et al. (2001) ; in the latter study, TULA mRNA could only be detected by RT-PCR, but not by Northern blotting, whereas we detected TULA mRNA using both techniques. However, it is also possible that the presence of RT-PCR products corresponding to TULA mRNA in some nonlymphoid samples (see Figure 2) indicates the expression of TULA in these tissues, albeit at a level substantially lower than that in lymphoid cells.
Two splice isoforms of TULA have been identified, of which the short one is expressed preferentially and binds to c-Cbl much better (see Figures 2 and 4) . Furthermore, the percentage of short TULA localized to the nucleus is significantly higher than that of long TULA (see Figure 3) . Considering that the sequence missing in short TULA lacks motifs of evident functional significance, long and short TULA may differ due to either variations of the overall protein structure or differential binding of regulatory proteins to the insert region. Clearly, further detailed studies are needed in order to elucidate the expression pattern of TULA in mammalian tissues and to determine the differential role of its splice isoforms.
Effects of TULA on PTK signaling and their possible mechanisms
Our experiments have indicated that the expression of TULA in 293T cells reduces c-Cbl-dependent downregulation of EGFR (see Figure 6 ). In particular, TULA counters the effect of c-Cbl on mature EGFR located on the cell surface (see Figure 6b ). In agreement with these results, TULA diminishes the negative effect of c-Cbl on SRE-driven transcription, a downstream target of EGFR-mediated signaling (see Figure 6c ). When studied in T cells, TULA behaves in agreement with its ability to inhibit c-Cbl-induced degradation of EGFR in 293T cells. Ectopically expressed wild-type TULA upregulates TCR/CD3-mediated signaling in Jurkat cells (see Figure 7a ), whereas an RNAi-induced decrease in the endogenous TULA expression suppresses this signaling (see Figure 7c) . The positive effect of TULA on TCR/ CD3-mediated signaling is likely to be due to its positive effect on Zap, a PTK targeted by c-Cbl in T cells, since a decrease in the endogenous TULA expression diminishes the TCR/CD3-induced activation of Zap in Jurkat cells (see Figure 7d ). It should be noted that the RNAiinduced modulation of TULA substantially reduced the kinase activity, but not the total protein level of Zap in T cells. This result is not unexpected, since it has been shown that c-Cbl-mediated downregulation of Syk, a Zap-related PTK, is caused by ubiquitylation and subsequent degradation of a minor fraction of the total pool of Syk in B cells, since only a minor fraction of Syk is tyrosine phosphorylated (Rao et al., 2001) .
Two lines of evidence developed in this study are important for further analysis of the molecular basis of TULA's effect on PTK signaling. First, the results indicating that TULA induces ubiquitylation and subsequent degradation of c-Cbl in the presence of EGFR (see Figures 6, 8) argue that the stabilizing effect of TULA on PTKs is mediated, at least in part, by the degradation of c-Cbl in the presence of TULA and PTKs. Second, since binding of TULA to ubiquitin may interfere with ubiquitylation in the c-Cbl/E2/PTK system, the contribution of TULA's UBA to the observed effects of TULA on c-Cbl, PTKs, and PTKmediated signaling has been analysed, and the overall conclusion reached in these experiments is that TULA's UBA is essential in the observed effects of TULA (see Figures 8c, d ). These findings are consistent with the following working model of TULA's effects. TULA is constitutively associated with c-Cbl and, thus, is recruited to a PTK that becomes associated with c-Cbl as a result of TKB-mediated interactions upon activation. By binding to the first ubiquitin transferred to this PTK, TULA protects the monoubiquitylated PTK from the transfer of additional ubiquitins and, as a result, retargets transfer of activated ubiquitin carried by a c-Cblassociated E2 enzyme to c-Cbl. However, several issues should be addressed further in order to elucidate the proposed model. Thus, although the TULA-induced degradation of c-Cbl appears to be mediated by the autoubiquitylation of c-Cbl (see Figure 8b) , it is possible that TULA may also act as an adaptor, which links cCbl to a protein facilitating the ubiquitylation of c-Cbl, such as Src (Yokouchi et al., 2001; Bao et al., 2003) or a specific E3 (Courbard et al., 2002; Magnifico et al., 2003) . (However, the possibility that TULA itself functions as a ubiquitylation factor specific for c-Cbl appears unlikely, since TULA lacks sequences characteristic for either E3 or E4 proteins, such as RING finger, U box, or HECT (Glickman and Ciechanover, 2002).) Furthermore, although the observed correlation between the effects of TULA on PTK activity and c-Cbl protein level, both of which are sensitive to the presence of a functional TULA's UBA, argues in favor of the TULA-dependent downregulation of c-Cbl being the reason for the upregulation of PTKs by TULA, it is possible that TULA stabilizes PTKs simply through a direct inhibition of the ubiquitin-mediated degradation of these PTKs. Indeed, the UBA-mediated binding of TULA to the first ubiquitin residues transferred to the targeted PTKs may prevent further ubiquitylation of these PTKs and/or the interactions of these PTKs with proteins that target them for degradation. The contribution of this effect and the TULA-induced downregulation of c-Cbl to the overall PTK-stabilizing effect of TULA needs to be evaluated further.
One might also speculate that the sequestration of cCbl by TULA provides an alternative explanation for the stabilizing effect of TULA on PTKs, but this explanation contradicts the finding that co-precipitation of c-Cbl and EGFR is not disrupted by either wild-type TULA or [DUBA]TULA (Figure 8d ). (Although an apparent decrease in the amount of c-Cbl co-precipitated with EGFR was detected in the presence of wildtype TULA upon EGF stimulation, this decrease can be explained entirely by a decrease in the total level of c-Cbl in these cells (Figure 8d) .) Finally, it should be noted that the effect of TULA on c-Cbl and PTKs, which we describe here, might not be the only effect of this novel protein. It is also possible that the UBA and SH3 domains of TULA allow this protein to function as an adaptor mediating interactions between c-Cbl and certain ubiquitylated proteins. Furthermore, the presence of UBA and SH3 in TULA is likely to render it capable of binding to multiple proteins, both ubiquitylated and not, thus enabling TULA to interfere with a number of cellular processes. Lastly, functions of the HCD domain of TULA remain enigmatic, and it cannot be ruled out that the effects of HCD unrelated to the effects of TULA described in this study may be crucial for the biological role of TULA. The exact nature of the mechanisms mediating the effects of TULA and their contribution to the overall biological function of this protein remain to be elucidated.
Regulation of the effects of TULA
Our results demonstrate that although TULA/c-Cbl interactions are constitutive, the effects of TULA are likely to be tightly controlled. It is clear that the blocking of PTK ubiquitylation and/or targeting for degradation by the UBA-mediated binding of TULA to (mono)ubiquitylated PTKs can only happen following activation of this PTK and its binding to c-Cbl. Furthermore, the TULA-mediated downregulation of the c-Cbl protein level is also dependent on the ability of c-Cbl to interact with activated EGFR in a TKBdependent fashion (see Figure 8b) . Moreover, TULA induces only degradation of c-Cbl molecules that can functionally interact with an E2 enzyme (see Figure 8b) . Therefore, TULA acts specifically on the molecules of cCbl that are currently capable of downregulating activated PTKs. This selectivity of TULA's effects should be able to prevent indiscriminate downregulation of c-Cbl in the cells expressing both c-Cbl and TULA at physiological levels. This notion is consistent with the observation that although Zap activity is substantially decreased in Jurkat cells expressing TULA siRNA (see Figure 7d ), the total level of c-Cbl protein is not significantly altered in these cells (data not shown).
Biological regulation of the effects of TULA on c-Cbl may be based on modulation of both the cellular level of TULA and the interactions between TULA, c-Cbl, and other relevant proteins. It is unlikely that tyrosine phosphorylation or ubiquitylation of TULA is involved in this regulation, since we failed to detect these modifications of TULA in our experiments (data not shown). However, a modest decrease in the association of TULA and c-Cbl caused by pervanadate stimulation (see Figures 5c, d) suggests that the effects of TULA are regulated by tyrosine phosphorylation of c-Cbl and/or other proteins that results in the disruption of binding between c-Cbl and TULA. Furthermore, the effects of TULA may be regulated by the disruption of TULA/cCbl interactions by other SH3-binding or SH3-containing proteins, as it has been shown, for example, for several PTKs (Alexandropoulos and Baltimore, 1996; Moarefi et al., 1997) . Finally, a possible role for HCD in the regulation of TULA cannot be ruled out.
Conclusions
We have identified and characterized the UBA-and SH3-containing protein TULA, which is primarily expressed in lymphoid cells. We have shown that TULA binds to c-Cbl and ubiquitin via its SH3 and UBA domains, respectively. We have also shown that TULA inhibits c-Cbl-mediated downregulation of PTKs. This effect of TULA appears to be mediated by the TULAinduced ubiquitylation and degradation of c-Cbl. Overall, this study favors the notion that TULA is a positive regulator of cell signaling mediated by PTKs, and, hence, may act as a promoter of cellular transformation. It is clear, however, that the biological role of the observed effects of TULA, as well as their specificity, regulation, and the exact molecular mechanisms, requires further investigation.
Materials and methods
Purification and identification of c-Cbl-associated proteins
JMC-D3 cells (2 Â 10 9 ) were lysed in 10 ml of TNLE buffer containing 50 mM Tris, 150 mM NaCl, 0.5 mM EDTA, 1% NP-40, 10 mM NaF, 1 mM Na 3 VO 4 , 1mM PMSF, 10 mg/ml leupeptin, and 10 mg/ml aprotinin (pH 7.4) on ice for 20 min. Lysate pre-cleared by centrifugation was mixed with 2 volumes of ice-cold start buffer (20 mM sodium phosphate, 0.2 M NaCl and 10 mM imidazole, pH 7.4) and loaded on a 5-ml HiTrap Ni 2 þ -chelation column (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The column was washed with 30 or 40 ml of ice-cold start buffer, and then eluted with two 10-ml portions of ice-cold sodium phosphate/NaCl buffer containing, in succession, 0.1 and 0.5 M imidazole. The 0.1 M-imidazole fraction containing the majority of c-Cbl was mixed with 1 ml of agarose-immobilized anti-c-Cbl (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 41C for 30 min. The suspension was transferred into a 5-ml column (BioRad, Hercules, CA, USA) and washed twice with 5 ml of ice-cold TBS with 0.1% NP-40 (pH 7.4). The antibody-bound material was eluted with 5 ml of 0.1 M glycine buffer (pH 3). All flowthrough, wash and elution fractions collected in the course of this purification were analysed using SDS-PAGE followed by silver (Silver Stain Plus, BioRad) or colloidal Coomassie (Colloidal Blue Stain, Invitrogen/Life Technologies, Carlsbad, CA, USA) staining.
Protein bands specific to the glycine elution lane, as well as two major bands of 53 and 63 kDa that were present in both the elution and the second wash lanes and a 48-kDa band that was present in the second, but not the first wash lane, were excised and digested with trypsin as previously reported . The resulting digests were analysed by on-line LC-ES MS/MS using reverse-phase capillary HPLC (C18, 75 mm Â 10 cm, 3-mm particles) coupled to an LCQ Deca ion-trap mass spectrometer equipped with an in-house-built nanoLC interface. Tryptic peptides were sequenced in a datadependent manner as they were eluted from the HPLC (Gatlin et al., 1998) . Uninterpreted spectra were searched against a nonredundant protein database using Mascot (Perkins et al., 1999) .
DNA constructs and mutagenesis
The first strand of cDNA was synthesized from total JMC-D3 RNA using AMV reverse transcriptase (Promega, Madison, WI, USA) and then amplified using Advantage-HF2 PCR kit (Clontech, Palo Alto, CA, USA) with TULA-specific primers: 5 0 -GGC AGG AAG AGA TGG CAG CG-3 0 (sense) and 5 0 -GAG GTT ATG ACA ACA TCA CCG TGG-3 0 (antisense). The PCR product was cloned into pcDNA3.1/V5-His TOPO vector (Invitrogen/Life Technologies). Positive clones were selected and sequenced on both strands. The obtained sequences of TULA were submitted to GenBank under accession numbers AF520809 (long) and AF521702 (short).
The KpnI/PmeI fragment of TULA cDNA from pcDNA3.1/ V5-His was subcloned into KpnI/SmaI sites of pAlterMAX (Promega) or BamHI/SmaI sites of pGEX2T (Amersham Pharmacia Biotech). Mutations were introduced into TULA using Pfu Turbo DNA polymerase (Stratagene, LaJolla, CA, USA) as described (Wang and Wilkinson, 2001) . The primers for UBA deletion were 5 0 -TGC AAT GAC CCT TCC CTA GAC GAC ATC CCC CA-3 0 (sense) and 5 0 -GCG GCT CTT GAG CTT GTT GGA GAC CTT GGC GTA GA-3 0 (antisense). The primers for W279L substitution were 5 0 -TCA CAG CGG ACG GGC TGC CGG GGC T-3 0 (sense) and 5 0 -GAT CCC AAT CAC CAG GCC CTC GCT GGT GGT C-3 0 (antisense). All mutations were verified by sequencing of both strands of DNA products.
Expression plasmids for c-Cbl have been described previously (Feshchenko et al., 1998; Teckchandani et al., 2001) . Briefly, 5Y-4F Cbl is a full-length c-Cbl in which tyrosines 674, 700, 731, 735, and 774 are mutated to phenylalanines, whereas 840-Cbl, HUT-Cbl, 480-Cbl, and v/c-Cbl are truncation mutants encompassing the first 840, 655, 480, and 357 amino-acid residues of c-Cbl, respectively. All Cbl coding sequences were HA-tagged. EGFR/pAlterMAX expression plasmid has been described previously . GSTUBAc, encoding for the GST-fused UBA domain of c-Cbl, and HA-ubiquitin/CMV expression plasmids were kindly provided by Drs S Lipkowitz (NIH, Bethesda, MD, USA) and D Bohmann (EMBL, Heidelberg, Germany), respectively.
The stable Jurkat-based cell lines with reduced TULA expression levels were obtained using the RNAi approach. The 19-nucleotide sequence corresponding to the fragment 640-658 of TULA (see Figure 1f) was selected as the target sequence. The double-stranded siRNA insert was generated using the forward and the reverse complementary oligonucleotides: 5 0 -CTA GAG CCT CCT TCG TGA GTT CAA GAG ACT CAC GAA GGA GGC TCT AGT TTT TT-3 0 (forward) and 5 0 -AAT TAA AAA ACT AGA GCC TCC TTC GTG AGT CTC TTG AAC TCA CGA AGG AGG CTC TAG GGC C3 0 (reverse complementary). The first 19 nucleotides of the forward oligonucleotide corresponding to the sense siRNA sequence are followed by a nine-nucleotide spacer, the reverse complementary antisense siRNA sequence and a stretch of six thymidines. The complementary oligonucleotide has, in addition, four-nucleotide overhangs compatible to EcoRI and ApaI sites. Annealed siRNA inserts were cloned into pSilencer 1.0-U6 expression vector (Ambion, Austin, TX, USA) digested with ApaI and EcoRI endonucleases. The obtained constructs were digested with BamHI in order to generate the U6 promoter/siRNA cassettes. The obtained cassettes were treated with the Klenow fragment in the presence of dATP and dGTP and ligated into pCE, a lentiviral gene transfer vector (Hasham and Tsygankov, 2004) , digested with XhoI and treated with the Klenow fragment in the presence of dTTP and dCTP. The specificity control vector was generated using the same approach, but was carrying the same TULA sequence in the opposite orientation (Elbashir et al., 2002) . The constructs were then verified by sequencing of both DNA strands. The obtained vectors were delivered to Jurkat cells using the previously described system (Hasham and Tsygankov, 2004) .
Cells
JMC-D3, a c-Cbl-overexpressing Jurkat clone, has been described previously (Reedquist et al., 1996; Rao et al., 2000) . Embryonal kidney 293T, Jurkat and MOLT-4 Tlymphoblastoid, Ramos B-lymphoma, HL-60 promyelocytic, A-549 lung carcinoma, HEp-2 derived from an epidermoid carcinoma of the larynx, HeLa cervical adenocarcinoma, K-562 erythroleukemia, and U-937 histiocytic (monocytic) lymphoma human cell lines and COS-7 embryonal kidney cell line from the African green monkey were obtained from ATCC. Jurkat, JMC-D3, MOLT-4, K-562, HL-60, and U-937 were grown in RPMI1640 with 10% fetal bovine serum. HEK293T, COS-7, A-549, HeLa, HEp-2, and Ramos cells were grown in DMEM with 10% fetal bovine serum. Peripheral blood mononuclear cells (PBMC) were isolated from donor blood using Ficoll-Paque (Amersham Pharmacia Biotech). T cells, B cells, and monocytes were isolated from PBMC using magnetic beads (Miltenyi Biotec, Auburn, CA, USA). 293T cells were transfected with DNA constructs using LipofectAmine-2000 (Invitrogen/Life Technologies). Flow cytometry analysis was performed as described previously (Hasham and Tsygankov, 2004) . The efficiency of transfection was determined as the percentage of green fluorescent cells following co-transfection of pEGFP-C2, a mammalian expression plasmid encoding for the enhanced green fluorescent protein (Clontech); it remained stable throughout the reported experiments at a level of 50-70%. 293T cells were activated, where indicated, with pervanadate as described previously (Feshchenko et al., 1998) or 100 ng/ml EGF (Sigma, St Louis, MO, USA) following 4-h serum starvation. Jurkat cells were stimulated with 1 mg/ml anti-CD3 OKT3 mAb, where indicated.
RNA purification, RT-PCR and Northern blot
Total RNA was extracted from cells using the RNAqueous-4PCR kit (Ambion). Multiple tissue Northern blot and total RNA from tissues were purchased from Clontech. RT-PCR was performed using the TITANIUM one-Step RT-PCR kit (Clontech) using 5 0 -ACT TCA AGA GTT CTG GAG A-3 0 (sense) and 5 0 -GGC TTC ACC ATC CTT TCT G-3 0 (antisense) primers. Subsequent nested PCR was performed using 5 0 -ACT TCA AGA GTT CTG GAG A-3 0 (sense) and 5 0 -AGG TCA GAT GCA GCT GTT TG-3 0 (antisense) primers. A DNA probe for Northern and Southern blots was obtained using PCR of TULA cDNA as a template with 5 0 -AGC CCC GCA GAC GTC ATC CG-3 0 (sense) and 5 0 -GGC TTC ACC ATC CTT TCT G-3 0 (antisense) primers and labeled with [a-32 P]ATP using primer extension. For real-time RT-PCR, total RNA was purified from 293T cells using the RNAqueous-4PCR kit (Ambion), and cDNA was synthesized using Oligo(dT) primers and AMV Reverse Transcriptase (Promega). Real-time PCR was then performed in the Rotor-Gene (Corbett Research, Sydney, Australia) with SYBR-Green (Molecular Probes, Eugene, OR, USA), Hot-Star Taq Polymerase (Qiagen, Valencia, CA, USA), and specific primers. The primers used were as follows: 5 0 -CCA TCG TGG TAG ATC CGT TT-3 0 (sense) and 5 0 -CCA GCC AAT TCC TTC ATC AT-3 0 (anti-sense) for c-Cbl, 5 0 -ATG CAG AAG GAG GCA AAG TG-3 0 (sense) and 5 0 -AGG TCA TCA ACT CCC AAA GG-3 0 (anti-sense) for EGFR, 5 0 -AGA AAA TCT GGC ACC ACA CC-3 0 (sense) and 5 0 -GGG GTG TTG AAG GTC TCA AA-3 0 (anti-sense) for b-actin, 5 0 -CGA CAA CCA CTA CCT GAG CA-3 0 (sense) and 5 0 -CTT GTA CAG CTC GTC CAT GC-3 0 (anti-sense) for EGFP. In each mRNA, a fragment of 100-150 bp was amplified using these primers. The threshold was set in the linear range of the amplification curve and the number of cycles required to reach the threshold was calculated for the genes analysed. The amount of c-Cbl and EGFR was normalized to b-actin (endogenous control) and EGFP (transfection control). The purity of the PCR products was established by melting analysis and agarose gel electrophoresis.
In vitro binding assays
Long and short TULA isoforms as well as the UBA domain of c-Cbl (UBAc) were produced as GST-fusion proteins as described previously (Tsygankov et al., 1994b; Feshchenko et al., 1998) . GST-TULA, GST-UBAc or GST (10 mg each) was mixed with the relevant cell lysate (2 mg of total protein) in a total volume of 1 ml and incubated at 41C for 60 min. Glutathione-agarose beads (Amersham Pharmacia Biotech) were then added (30 ml), and samples were rotated at 41C for an additional 60 min and collected by centrifugation. The analysis of binding of c-Cbl and TULA to ubiquitin was essentially identical, but agarose-immobilized ubiquitin (30 ml) (Boston Biotech, Cambridge, MA, USA) was added. In both cases, the beads were extensively washed, and the attached proteins were analysed using SDS-PAGE followed by immunoblotting.
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting was carried out essentially as described previously (Tsygankov et al., 1994b; Feshchenko et al., 1998) using modified lysis and wash buffers. Lysis buffer contained 50 mM Tris, 1% NP-40, 150 mM NaCl, 1 mM EGTA, 10% glycerol, 1 mM Na 3 VO 4 , 1 mM PMSF, and 10 mg/ml each pepstatin A, leupeptin, and aprotinin (pH 7.4). Immunoprecipitation was carried out using Pansorbin (Calbiochem, La Jolla, CA, USA), unless indicated otherwise. The wash buffer contained 20 mM HEPES, 0.1% Triton X-100, 150 mM NaCl, and 10% glycerol (pH 7.5). Blots were visualized using an ECL Plus chemiluminescence kit (Amersham Pharmacia Biotech), and quantified using an Astra 1220S Scanner (UMAX, Fremont, CA, USA) and the NIH Image or Un-scan-it (Silk Scientific, Orem, UT, USA) software.
Reporter assays
The firefly luciferase-based reporter plasmid NF-AT/GL3 (Merlo and Tsygankov, 2001 ) and SRE/XP-2 contained, respectively, three copies of the distal NF-AT sites of human IL-2 promoter and the regulatory sequence of Egr-1 promoter. 293T cells were transfected using LipofectAmine-2000 with the cDNA expression constructs indicated, SRE/XP-2 (3.2 mg per 1 Â 10 6 cells) and pRL-null (Promega), a transfection efficiency control plasmid encoding for Renilla luciferase (0.4 mg per 1 Â 10 6 cells). Jurkat cells were transfected using DMRIE-C with the cDNA expression constructs indicated, NF-AT/GL3 (5.4 mg per 1 Â 10 7 cells) and pRL-null (0.6 mg per 1 Â 10 7 cells). The assay was performed using a Dual-Luciferase Assay System (Promega) as described previously (Merlo and Tsygankov, 2001 ).
Subcellular fractionation
293T cells were harvested and fractionated 48 h after transfection as described (Hartley and Corvera, 1996) . Briefly, the cells were resuspended in ice-cold hypotonic buffer and disrupted using a Dounce homogenizer. Tonicity was restored by the addition of hypertonic buffer. Unbroken cells were removed by centrifugation at 250 g for 5 min at 41C, and nuclei were then precipitated at 750 g for 5 min at 41C. The nuclear pellet was resuspended in extraction buffer, and the nuclear fraction was prepared as described (Schreiber et al., 1989) . The postnuclear supernatant was centrifuged at 100 000 g for 50 min at 41C in the presence of 5 mM EDTA. The supernatant and the pellet were considered the cytosolic and the membrane fractions, respectively. Samples from each fraction were analysed using immunoblotting with anti-TULA and quantified as described above. The purity of the fractions was controlled by immunoblotting for H1 histone and GAPDH.
EGFR downregulation assay
293T cells were transfected with 1 mg EGFR, 2.5 mg c-Cbl, 9 mg TULA, and 2.5 mg HA-ubiquitin expression plasmids per 100-mm plate containing 6 Â 10 6 cells. Matching doses of pAlter-MAX were added to transfections, to which not all plasmids were added (EGFR only, EGFR plus c-Cbl). After transfection cells were re-seeded into fibronectin-coated 24-well plates. Cell monolayers were analysed in these plates as described in . Briefly, cells were incubated without or with 250 ng/ml EGF at 371C for varying periods of time. Downregulation was stopped by washing cells with ice-cold buffer and placing them on ice. Surface-bound EGF was removed by using an acetic acid wash. The number of ligandbinding sites was then determined by incubating cells with 125 I-EGF on ice for 2 h. Nonspecific binding was determined in the presence of a 100-fold excess of unlabeled EGF. Radiolabeling of EGF was carried out using Na[ 125 I] (ICN, Irvine, CA, USA) and IODO-GEN (Pierce, Rockford, IL, USA) as described in Waterman et al. (1998) .
Antibodies
The affinity-purified polyclonal antibodies to c-Cbl (C-15), CrkL (C-20), EGFR (1005, used for immunoblotting), Tyr-1173-phosphorylated EGFR, ubiquitin (FL-76) , and HA (Y-11), as well as the anti-phosphotyrosine mAb (PY20), were purchased from Santa Cruz Biotechnology. The rabbit polyclonal antiserum to PI-3 0 kinase p85 and the mouse monoclonal antibody to EF-1a were purchased from UBI (Lake Placid, NY, USA). Anti-EGFR (E12020) and anti-Rac1 (R56220) mAb's were purchased from Transduction Laboratories/Pharmingen (San Diego, CA, USA). Anti-V5 mAb (46-0705) was purchased from Invitrogen/Life Technologies. Anti-GAPDH mAb (6C5) was purchased from Research Diagnostic (Flanders, NJ, USA). Anti-CD3 mAb (OKT3) was purified using affinity chromatography of hybridoma supernatant on protein A. FITC-labeled anti-mouse IgG was purchased from Molecular Probes (Eugene, OR, USA). Anti-H1 histone mAb (MRA12) was kindly provided by Dr M Monestier (Temple University School of Medicine, Philadelphia, PA, USA). Anti-Zap rabbit polyclonal serum was described previously (Tsygankov et al., 1994a) . Affinitypurified rabbit polyclonal antibodies to TULA were produced using a KLH-conjugated synthetic peptide corresponding to amino acids 322 and 341 of the long form of TULA (Bethyl Laboratories, Montgomery, TX, USA).
Statistical analysis of data
Statistical analysis of data was carried out using the GraphPad Prism software (version 3.0 for Macintosh; GraphPad, San Diego, CA, USA).
Abbreviations LZ, leucine zipper; PTK, protein tyrosine kinase; siRNA, short interfering RNA; RNAi, RNA interference; TKB, tyrosine kinase-binding domain; TCR, T-cell receptor for antigen; UBA, ubiquitylation-associated domain.
